The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.

Objective: To investigate the effect of Mometasone furoate (Elocon Cream) Nasal Spray (MFNS) treatment on hearing secretory ... The control group was given conventional oral drug treatment, including ...

The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical company Johnson & Johnson created the spray from esketamine, a more potent ...

But a generic version (and the active ingredient) of this popular medication, sildenafil, is widely available from several drug manufacturers at a fraction of the cost. Here’s more about this ...

for its Abbreviated New Drug Application (ANDA) for ipratropium bromide nasal solution (nasal spray), 0.06%, to market a generic equivalent of Atrovent nasal spray, 0.06%, of Boehringer Ingelheim ...

has accepted for review the New Drug Application (NDA) for its novel Bumetanide Nasal Spray (RSQ-777). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of September 14, ...

has accepted for review the New Drug Application (NDA) for its novel Bumetanide Nasal Spray (RSQ-777). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of September 14, ...

Johnson & Johnson's nasal spray received US FDA approval The nasal spray is used for the treatment of major depressive disorder The drug brought in sales of $780 million in 2024 The US Food and Drug ...

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an ...

Got a tip? Send it to The Daily Beast here. ADVERTISEMENT ADVERTISEMENT ...